Join the Oncology Voice Network. Join for Free
Season 2, Episode 17: Ode To The Oncopig with Jessicca Rege

Season 2, Episode 17: Ode To The Oncopig with Jessicca Rege


Share This Article


Summary

Welcome to The Pharmaverse Podcast, your go-to destination for insights in the pharmaceutical and biotech industry. In this episode, host Michael Pietrack sits down with Jessicca Rege, PhD, CEO of Seuss Clinicals, to discuss pioneering approaches in preclinical oncology research using the Oncopig cancer model.

Jessica shares her experience leading innovative pharma projects, her thoughts on disruptive and transformational leadership, and practical advice for aspiring leaders in the pharmaceutical and biotech sectors. Learn how her team is advancing preclinical oncology research, moving therapies to patients faster, and redefining leadership in Pharma.

Subscribe to stay updated with the latest episodes and gain insights from the brightest stars across the Pharma universe!

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN